Leiden, November 12, 2021 – MyLife Technologies has raised €3.5 million from Fare Capital BV, SAL Beheer BV, informal investors and the existing shareholders. With this capital, MyLife in Leiden will start the production of the vaccine patches for clinical studies and invest with partners in demonstration projects against COVID-19, HPV and in vaccine therapy against certain types of cancer.
We foresee a next series A investment round of around €15 million in early 2023 for the construction of a pilot plant and expansion of activities to the US and Asia.
In addition, MyLife Technologies has received non-dilutive funding in the form of grants and loans:
- December 2020 - MIT R&D grant to ddevelop rapid response vaccination technology using polymeric nano particles for mRNA and DNA delivery
- March 2020 - EU InnoWide grant, to research the feasibility iof HPV vaccine patches for Low and Middel Income Countries
- December 2018 - Uniiq Loan by Innovation Quarter, to perform a.o. the First-in-Human studies in 2019
- NanoLabNL Voucher (The Netherlands)
- STW Take-Off Grant (Stichting voor de Technische Wetenschappen, The Netherlands): 2015 – 2017
- In addition, 2 applications to the collaborative research program ADITEC (Advanced Immunization Technologies) were honored: 2016 - 2017
- Internationaal Innoveren (RVO / Ministry of Economic Affairs, The Netherlands): 2012 – 2015
For further enquiries with respect to investment, please send an email to: